Ironwood Pharmaceuticals | IRWD - Cash And Equivalent


Ironwood Pharmaceuticals reported $140.41M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 819.69M 27.33M Dec/2025
Agios Pharmaceuticals USD 89.13M 3.58M Dec/2025
Akebia Therapeutics USD 184.84M 18.4M Dec/2025
Almirall EUR 337.77M 14.83M Dec/2025
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
Amarin USD 122.8M 25.08M Sep/2025
Ardelyx USD 68M 25.28M Dec/2025
Astellas Pharma JPY 188.37B 8.51B Mar/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Charles River Laboratories USD 213.77M 6.67M Dec/2025
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Ironwood Pharmaceuticals USD 140.41M 47.56M Sep/2025
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Myriad Genetics USD 149.6M 4.2M Dec/2025
Pacira USD 158.54M 10.96M Dec/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Takeda JPY 654.94B 26.55B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025